News

Filter

Current filters:

Neurological

1 to 9 of 1736 results

FDA safety review of Zyprexa Relprevv calls for no changes to current prescribing

24-03-2015

The US Food and Drug Administration has concluded a review of a study undertaken to determine the cause…

Eli LillyHealthcareNeurologicalPharmaceuticalRegulationUSAZyprexa Relprevv

Pfizer and Lilly gear up to resume Phase III chronic pain program for tanezumab

23-03-2015

US pharma majors Pfizer and Eli Lilly both saw their shares rise in pre-market trading today, as they…

Eli LillyLicensingNeurologicalPfizerPharmaceuticalRegulationUSA

Aurobindo gains tentative US FDA approval for generic Vimpat

21-03-2015

Indian drugmaker Aurobindo Pharma has received tentative approval from the US Food and Drug Administration…

Aurobindo PharmaGenericslacosamide Tablet and InjectionLegalNeurologicalRegulationUCBUSAVimpat

Biogen Idec shares up on positive early-stage results for Alzheimer’s candidate aducanumab

20-03-2015

US biotech major Biogen Idec has announced data from a pre-specified interim analysis of PRIME, the Phase…

aducanumabBIIB037Biogen IdecBiotechnologyNeurologicalResearch

AbbVie and C2N ink global license deal for Alzheimer's disease therapy

AbbVie and C2N ink global license deal for Alzheimer's disease therapy

19-03-2015

US drugmaker AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a…

AbbVieBiotechnologyC2N DiagnosticsGlobalLicensingNeurological

BIAL’s opicapone significantly improves OFF-time in fluctuating Parkinson’s

19-03-2015

Privately-held Portuguese drugmaker BIAL today announced positive results from a Phase III, randomized,…

BIALNeurologicalopicaponePharmaceuticalResearch

Positive final Phase IIa safety results for Neurotrope’s Alzheimer's drug

Positive final Phase IIa safety results for Neurotrope’s Alzheimer's drug

17-03-2015

US orphan disease specialist Neurotrope saw its shares rise over 5% to $1.25 after it released secondary…

bryostatin-1NeurologicalNeurotropePharmaceuticalResearch

Lilly, GSK and Janssen join UK government's $100 million Dementia Discovery Fund

Lilly, GSK and Janssen join UK government's $100 million Dementia Discovery Fund

17-03-2015

The UK’s Health Secretary Jeremy Hunt has announced a collaborative dementia research initiative between…

Eli LillyGSKJanssenNeurologicalPharmaceuticalResearchUK

1 to 9 of 1736 results

Back to top